Diagnostic Utility of Neuregulin for Acute Coronary Syndrome

Abstract EN

The purpose of this study was to determine the diagnostic test characteristics of serum neuregulin-1β (NRG-1β) for the detection of acute coronary syndrome (ACS).

We recruited emergency department patients presenting with signs and symptoms prompting an evaluation for ACS.

Serum troponin and neuregulin-1β levels were compared between those who had a final discharge diagnosis of myocardial infarction (STEMI and NSTEMI) and those who did not, as well as those who more broadly had a final discharge diagnosis of ACS (STEMI, NSTEMI, and unstable angina).

Of 319 study participants, 11% had evidence of myocardial infarction, and 19.7% had a final diagnosis of ACS.

Patients with MI had median neuregulin levels of 0.16 ng/mL (IQR [0.16–24.54]).

Compared to the median of those without MI, 1.46 ng/mL (IQR [0.16–15.02]), there was no significant difference in the distribution of results (P=0.63).

Median neuregulin levels for patients with ACS were 0.65 ng/mL (IQR [0.16–24.54]).

There was no statistical significance compared to those without ACS who had a median of 1.40 ng/mL (IQR [0.16–14.19]) (P=0.95).

Neuregulin did not perform successfully as a biomarker for acute MI or ACS in the emergency department.